[go: up one dir, main page]

WO2003033696A1 - Vegf antisense compound - Google Patents

Vegf antisense compound Download PDF

Info

Publication number
WO2003033696A1
WO2003033696A1 PCT/JP2002/010796 JP0210796W WO03033696A1 WO 2003033696 A1 WO2003033696 A1 WO 2003033696A1 JP 0210796 W JP0210796 W JP 0210796W WO 03033696 A1 WO03033696 A1 WO 03033696A1
Authority
WO
WIPO (PCT)
Prior art keywords
antisense compound
vegf antisense
different
same
vegf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2002/010796
Other languages
French (fr)
Japanese (ja)
Inventor
Makoto Koizumi
Koji Morita
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sankyo Co Ltd
Original Assignee
Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co Ltd filed Critical Sankyo Co Ltd
Publication of WO2003033696A1 publication Critical patent/WO2003033696A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A compound represented by the general formula HO-B1-B2-B3-B4-B5-B6-B7-B8-B9-B10-B11-B12-B13-B14-B15-B16-B17-B18-B19-B20-B21-B22-H (wherein B1 to B3, B8, B11, and B20 are the same or different and each represents Cp, etc.; B4, B5, B7, B9, B12, B14 to B16, and B21 are the same or different and each represents Ap, etc.; B6, B10, B13, and B17 are the same or different and each represents Gp, etc.; B18 and B19 are the same or different and each represents Tp, etc.; and B22 represents Tt, etc.); and a pharmacologically acceptable salt of the compound.
PCT/JP2002/010796 2001-10-18 2002-10-17 Vegf antisense compound Ceased WO2003033696A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001/320096 2001-10-18
JP2001320096 2001-10-18

Publications (1)

Publication Number Publication Date
WO2003033696A1 true WO2003033696A1 (en) 2003-04-24

Family

ID=19137535

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/010796 Ceased WO2003033696A1 (en) 2001-10-18 2002-10-17 Vegf antisense compound

Country Status (1)

Country Link
WO (1) WO2003033696A1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998039352A1 (en) * 1997-03-07 1998-09-11 Takeshi Imanishi Novel bicyclonucleoside and oligonucleotide analogues
WO1999014226A2 (en) * 1997-09-12 1999-03-25 Exiqon A/S Bi- and tri-cyclic nucleoside, nucleotide and oligonucleotide analogues
WO2000047599A1 (en) * 1999-02-12 2000-08-17 Sankyo Company, Limited Novel nucleosides and oligonucleotide analogues

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998039352A1 (en) * 1997-03-07 1998-09-11 Takeshi Imanishi Novel bicyclonucleoside and oligonucleotide analogues
WO1999014226A2 (en) * 1997-09-12 1999-03-25 Exiqon A/S Bi- and tri-cyclic nucleoside, nucleotide and oligonucleotide analogues
WO2000047599A1 (en) * 1999-02-12 2000-08-17 Sankyo Company, Limited Novel nucleosides and oligonucleotide analogues

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHRISTENSEN U. ET AL.: "Stopped-flow kinetics of locked nucleic acid(LNA)-oligonucleotide duplex formation: studies of LNA-DNA and DNA-DNA interactions", BIOCHEM. J., vol. 354, no. 3, 15 March 2001 (2001-03-15), pages 481 - 484, XP002971047 *
KUMAR R. ET AL.: "The first analogues of LNA(locked nucleic acids): phosphorothioate-LNA and 2'-THIO-LNA", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 8, no. 16, 1998, pages 2219 - 2222, XP002094302 *
NOMURA M. ET AL.: "Possible participation of autocrine and paracrine vascular endotherial growth factors in hypoxia-induced proliferation of endotherial cells and pericytes", J. BIOL. CHEM., vol. 270, no. 47, 1995, pages 28316 - 28324, XP002915173 *
SATOSHI OBIKA: "Tobu rittai haiza o kotei shita jinko nucleoside oyobi oligonucleotide-rui no gosei to sono tokusei", JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, vol. 120, no. 2, 2000, pages 147 - 158, XP002971048 *

Similar Documents

Publication Publication Date Title
WO2004108715A8 (en) 3-aryloxy and 3-heteroaryloxy substituted benzo(b) thiophenes as therapeutic agents with pi3k activity
PL368739A1 (en) Acetylene derivatives having mglur 5 antagonistic activity
WO2004056322A3 (en) Antibiotics containing borinic acid complexes and methods of use
CA2497074A1 (en) Substituted spirocyclic ketoenols
WO2006007384A3 (en) Antibiotics containing borinic acid complexes and methods of use
WO2001014376A8 (en) Novel spiro compounds
MXPA06000675A (en) Quinolone derivative or salt thereof.
IL173269A0 (en) Compounds for inflammation and immune-related uses
WO2002062775A1 (en) 2-acylaminothiazole derivative or its salt
TW200621232A (en) Compounds for inflammation and immune-related uses
WO2005042497A3 (en) Benzimidazoles useful as modulators of ion channels
WO2005058888A3 (en) Oxazolidinone-quinolone hybrid antibiotics
WO2009064374A3 (en) Oral formulations of bis(thiohydrazide amides)
PE20030061A1 (en) 1-BIARIL-1,8-NAPHTHYRIDIN-4-ONA AS PHOSPHODIESTERASE-4 INHIBITORS
MXPA05013210A (en) Cycloalkylsulfanyl substituted benzo[b]thiophenes as therapeutic agents.
MXPA05012953A (en) 3-arylsulfanyl and 3-heteroarylsulfanyl substituted benzo[b]thiophenes as therapeutic agents.
PL359763A1 (en) Fungicidal combinations of active agents
WO2002017854A3 (en) Cephalosporin antibiotics and prodrugs thereof
MX2007000240A (en) Phenyl substituted [1.2]-oxazine-3,5-dione and dihydropyrone derivatives.
WO2004043928A8 (en) N-sulfonyl-4-methyleneamino-3-hydroxy-2-pyridones as antimicrobial agents
WO2003033696A1 (en) Vegf antisense compound
TW200602295A (en) Organic compounds
TW200613251A (en) Organic compounds
WO2003097585A3 (en) Amidoacetonitrile compounds
IL196418A0 (en) Thieno[3,2-c]pyridine-7-carboxylic acid derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP